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Results: Generally, in comparison to
values found in healthy subjects (MDA
= mol/L), both in women with cervical
/-!mol/L; TRAP = 598.88 ± 81.65 /-!4.36
± 0.82 mol/L) and in women/-!mol/L; TRAP
= 755.24 ± 248.99 /-!carcinoma (MDA
= 4.83 ± 1.40 mol/L; TRAP = 799.78
± 238.04/-!with uterine carcinoma (MDA
= 5.24 ± 1.54 mol/L), there were signify-
cantly increased concentrations of MDA
(P = 0.05 and/-! P = 0.0139, respectively)
and of TRAP antioxidant activity
(P = 0.0001 and P = 0.0002, respectively).
No relationship was found between clinical
staging and MDA concentration, neither
in cervical nor uterine carcinoma. In con-
trast, TRAP antioxidant activity increased
significantly with clinical staging of cervical
carcinoma from FIGO 1° to IW(there were
no FIGO IVo patients), and with clinical
staging of uterine carcinoma from FIGO 1°
to W to IVO. In FIGO IW, there were only
2 uterine carcinoma patients, a fact ma-
king the data interpretation statistically
inadequate.
Conclusions: Soth in women with
cervical carcinoma and uterine carcinoma,
there are increased serum levels of a
marker of lipid peroxidation (MDA) and of
TRAP antioxidant activity. Clinical staging
of cervical and uterine carcinoma does not
affect the serum concentration of MDA.
However, TRAP antioxidant activity shows
an increase along with the clinical
progression of the carcinoma. We think
that the high TRAP antioxidant activity
found in cases of the studied carcinomas
may testify to the long-term preservation of
mechanisms defending the macroorga-
nism from the sequelae of peroxidation.
S298
231.
SYNCHRONOUS AND METACHRO-
NOUS BILATERAL BREAST CAN-
CER - A COMPARISON OF CLINI-
CAL, HISTOPATHOLOGICAL
FEATURES OF THE FIRST AND SE-
COND PRIMARY BREAST CANCER
AND BRCA 1 AND 2 MUTATIONS
Nowicka E., Rogozinska J.,
Grzybowska E., Behrendt K.,
Mucha-Matecka A., Tarnawski R.
Center of Oncology, MCS Memorial Institute,
Gliwice
Purpose: to evaluate the clinical,
histopathological features of the first and
second primary breast cancer in patients
with bilateral breast cancer and to
determine the contribution of SRCA 1 and
2 mutations in SSC.
Material and methods: 131 patients
treated at Institute of Oncology MCS
Memorial in Gliwice between 1969-2002
developed bilateral breast cancer/SSC/.
There were 39 /29,7 %/synchronous and
92 /70,3%/ metachronous SSC. SRCA 1
and 2 mutations analysis was performed in
92 patients.
Results: Mean age of diagnosis of
cancer in SSSC and MSSC group was 52
and 46 /p=O, 002/.The proportion of early
stage tumors was significantly higher in
opposite side tumors compared to the first
primary tumor in both groups /p<O,OOOll.
The mean tumor diameter of first primary
and opposite breast tumors were 3,6 and
2,4 cm/p<0,00001/. A number of positive
correlations existed between tumors in
both breast in SSSC and MSSC-the
presence of ductal histology /p=0,002/, the
ER and PR status in SSSC /p<0,05/.
SRCA 1 and 2 mutations were recognized
in 27 % patients. All but two mutations
were detected in MSSC /p =0,006/.
Median follow-up from the diagnosis
of primary and SSC was 9,34 and 3,78
years. Five year DFS for SSSC and MSBC
were 67 and 93% respectively; MFS were
76 and 97%, RFS were 77 and 95%/ p<O,
05/. If the same analysis was performed
since the date of the second breast tumor
DFS, MFS and RFS did not reach
statistical significance in both groups.
Rep. Praet. Oneal. Radiother. 8 (81) 2003
Conclusions: 1. A close follow-up policy
enables detection the second breast
cancer at an earlier stage than the primary
one. 2. SBBC and MBBC seem to be
different set of tumors in term of clinical
characteristics and survival.
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IL-15 INHIBITS SPONTANEOUS
APOPTOSIS OF CD4+ AND CD8+
PERIPHERAL BLOOD T
LYMPHOCYTES FROM PATIENTS
WITH MELANOMA
Osawa T., Kaczmarek A., Kowalczyk D.,
Bogusz-Osawa M., Mackiewicz A.
Department of Cancer Immunology,
Poznan School of Medical Sciences,
Wielkopolski Cancer Center, ul. Garbary 15,
61-866 Poznan, Poland
CD4+ and CD8+ T lymphocytes from the
peripheral blood of melanoma patients are
prone to undergo spontaneous apoptosis
when compared with healthy individuals.
The rapid lymphocyte turnover and the
loss of CD4+ and CD8+ T cells may cause
the weak antitumor response in cancer
patients. Since CD4+ and CD8+ T cell
mediated immune responses play an
important role in controlling the antitumor
response, enhancing the survival and
function of these T cells may improve the
disease outcome of melanoma patients. In
our experiment, we tried to see the effect
of interleukin 15 (IL-15) on the spon-
taneous apoptosis of peripheral blood
mononuclear cells (PBMCs) from patients
with melanoma. The PBMCs obtained
from 16 melanoma patients and 16 healthy
controls were incubated overnight in
medium with or without IL-15: The PBMCs
were then stained for CD4+ or CD8+ cells
and evaluated for apoptosis with the
Annexin V binding method using a
multicolor flow cytometry. The results
showed that IL-15 inhibits spontaneous
apoptosis in CD4+ and CD8+ T cells in
both melanoma patients and healthy
individuals. IL-15 significantly reduced
6.3% (mean±spontaneous apoptosis of
CD8+ T-cells in melanoma patients from
26 8.7% (n=16, P± SO) to 19 ±< 3.4%
to±0.005) and in healthy controls from 15
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3.4% (n=16, P±11 <0.005). There was a
similar result with CD4+ cells with 7.3%±
6.7% to 17 ±IL-15 reducing the apoptosis
in melanoma patients from 22 (n=16, P<
4.0% (n=16,± 4.1 % to 9 ±.005) and in
healthy controls form 12 P<.005). IL-15
may thus prove useful in a therapeutic
immunostimulation strategy for melanoma
patients
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FAS+ CD4+ AND FAS+ CD8+ CELLS
FROM THE PERIPHERAL BLOOD
OF MELANOMA PATIENTS PREFE-
RENTIALLY BIND ANNEXIN V
Osawa T., Kaczmarek A., Kowalczyk D.,
Bogusz-Osawa M., Mackiewicz A.
Department of Cancer Immunology,
Poznan School of Medical Sciences,
Wielkopolski Cancer Center, ul. Garbary 15,
61-866 Poznan, Poland
Malignant melanoma is resistant, except
for a small percent, to treatments such as
radio and chemotherapy. On the other
hand melanoma has been considered as
the prototypical immunogenic tumor in
which the immune system may have a role
in the outcome of the disease. Immune
cells from cancer patients respond poorly
to mitogenic or antigenic stimuli. One
reason for this is the rapid turn over of the
T lymphocytes arising from the apoptosis
of these cells. The induction of apoptosis
in the activated T lymphocytes is
considered as one of the ways the tumor
cells avoid recognition and destruction.
The Fas (APO-1, CD95)/FasL pathway is
well know to induce apoptotic cell death
in many cells. In this study the expression
of Fas and its correlation withapoptosis
on CD4+ and CD8+ T cells in PBMCs from
melanoma patients was measured.
Annexin V was used to measure apo-
·ptosis. For the present study, we obtained
5ml of venous blood from 16 pa-tients and
10 healthy controls. The lymphocytes were
then isolated using the Ficoll-Hypaque
gradient centrifugation. The lymphocytes
were then incubated in medium for 24hrs
and then stained with PerCP-labled
monoclonal antibodies of anti CD4 or anti
CD8. They were then washed and stained
S299
